Finance

Lists
0775:HKG
CK Life Sciences Intl (Holdings) Inc
HK$0,51
0,00%
(0,00) 1D
16 Okt., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 0775...
Open
HK$0,51
High
HK$0,52
Low
HK$0,51
Mkt. cap
4,90 mjd
Avg. vol.
1,66 m
Volume
956,00 k
52-wk high
HK$1,02
52-wk low
HK$0,51
EPS
-HK$0,01
Shares outstanding
9,61 mjd
No. of employees
2 k
Open
HK$0,51
High
HK$0,52
Low
HK$0,51
Mkt. cap
4,90 mjd
Avg. vol.
1,66 m
Volume
956,00 k
52-wk high
HK$1,02
52-wk low
HK$0,51
EPS
-HK$0,01
Shares outstanding
9,61 mjd
No. of employees
2 k
News stories
From web sources and news partners
Profile
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Victor Li Tzar-kuoi, the eldest son of Li Ka-shing, the chairman of Cheung Kong Holdings. It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008. CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector. The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
About CK Life Sciences Intl (Holdings) Inc
CEOYing Choi Yu
Employees1,92 k
Founded2000
Headquarters-
Sector-
Previous reportsAll values in HKD
Loading Previous Earnings...
Revenue
Net income
All values in HKD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,40 mjd
1,40 mjd
1,36 mjd
1,36 mjd
Cost of goods sold
1,01 mjd
1,01 mjd
975,61 m
975,61 m
Cost of revenue
1,01 mjd
1,01 mjd
975,61 m
975,61 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
187,01 m
187,01 m
173,47 m
173,47 m
Operating expense
440,32 m
440,32 m
339,26 m
339,26 m
Total operating expenses
1,45 mjd
1,45 mjd
1,31 mjd
1,31 mjd
Operating income
-48,67 m
-48,67 m
43,01 m
43,01 m
Other non operating income
16,60 m
16,60 m
9,78 m
9,78 m
EBT including unusual items
58,42 m
58,42 m
-9,29 m
-9,29 m
EBT excluding unusual items
-87,93 m
-87,93 m
-9,29 m
-9,29 m
Income tax expense
77,23 m
77,23 m
15,02 m
15,02 m
Effective tax rate
132,19%
132,19%
-161,72%
-161,72%
Other operating expenses
231,88 m
231,88 m
143,42 m
143,42 m
Net income
-17,98 m
-17,98 m
-14,36 m
-14,36 m
Net profit margin
-1,28%
-1,28%
-1,06%
-1,06%
Earnings per share
-
-
-
-
Interest and investment income
5,36 m
5,36 m
3,26 m
3,26 m
Interest expense
-61,80 m
-61,80 m
-65,24 m
-65,24 m
Net interest expenses
-56,44 m
-56,44 m
-61,97 m
-61,97 m
Depreciation and amortization charges
20,80 m
20,80 m
21,66 m
21,66 m
EBITDA
11,09 m
11,09 m
65,38 m
65,38 m
Gain or loss from assets sale
-346,73 m
-346,73 m
-
-
AI content may include mistakes. Learn more
Google-programme